Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 20.11.2017 | EN | Official Journal of the European Union | C 392/25 |

---

Judgment of the General Court of 5 October 2017 — Forest Pharma v EUIPO — Ipsen Pharma (COLINEB)

(Case T-36/17)[(1)](#ntr1-C_2017392EN.01002501-E0001)

((EU trade mark - Opposition proceedings - Application for EU word mark COLINEB - Earlier national figurative mark Colina - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation No 207/2009 (now Article 8(1)(b) of Regulation (EU) 2017/1001) - Extent of the examination to be carried out by the Board of Appeal - Article 76(1) of Regulation No 207/2009 (now Article 95(1) of Regulation (EU) 2017/1001)))

(2017/C 392/31)

Language of the case: English

Parties

Applicant: Forest Pharma BV (Amsterdam, Netherlands) (represented by: T. Holman, Solicitor)

Defendant: European Union Intellectual Property Office (represented by: P. Sipos, acting as Agent)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Ipsen Pharma SAS (Boulogne-Billancourt, France) (represented by: E. Baud, lawyer)

Re:

Action brought against the decision of the Fifth Board of Appeal of EUIPO of 13 October 2016 (Case R 500/2016-5), relating to opposition proceedings between Ipsen Pharma and Forest Pharma.

Operative part of the judgment

The Court:

|  |  |
| --- | --- |
| 1. | Dismisses the action; |

|  |  |
| --- | --- |
| 2. | Orders Forest Pharma BV to bear its own costs and to pay the costs incurred by the European Union Intellectual Property Office (EUIPO); |

|  |  |
| --- | --- |
| 3. | Orders Ipsen Pharma SAS to bear its own costs. |

---

[Top](#document1)